Acetaminophen Hepatotoxicity

1. Disease Information

Overview

Acetaminophen (APAP) hepatotoxicity is a dose-dependent, predictable form of drug-induced liver injury (DILI) caused by overdose of acetaminophen (paracetamol), the world's most widely used analgesic/antipyretic. It represents the clinically most relevant drug hepatotoxicity in Western countries and is the leading cause of acute liver failure (ALF) in the United States and the United Kingdom (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3). The condition results from the excessive generation of the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450 enzymes, primarily CYP2E1, which overwhelms hepatic glutathione (GSH) detoxification capacity and triggers a cascade of mitochondrial dysfunction, oxidant stress, and programmed necrotic cell death in centrilobular hepatocytes (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3).

Key Identifiers and Synonyms

The following table summarizes core disease identifiers:

Table: This table summarizes core identifiers, synonyms, mechanistic hallmarks, affected anatomy, and high-yield epidemiology for acetaminophen hepatotoxicity. It is useful as a compact knowledge-base entry scaffold anchored to retrieved evidence.

Common Synonyms: Paracetamol hepatotoxicity, acetaminophen-induced liver injury (AILI), paracetamol-induced liver injury, APAP hepatotoxicity, APAP-induced acute liver failure, acetaminophen overdose hepatotoxicity, paracetamol poisoning liver damage.

Key Identifiers: - ICD-10: T39.1 (Poisoning by 4-aminophenol derivatives) - MeSH: D056486 (Drug-Induced Liver Injury) - MONDO: MONDO:0005359 (drug-induced liver injury); specific APAP hepatotoxicity sub-ID not established in MONDO at this time - CHEBI: CHEBI:46195 (acetaminophen/paracetamol)

The information in this report is derived from aggregated disease-level resources including clinical registries (Acute Liver Failure Study Group), systematic reviews, mechanistic studies in animal models, and clinical cohorts.

2. Etiology

Disease Causal Factors

Acetaminophen hepatotoxicity is caused directly by supratherapeutic doses of acetaminophen. The primary mechanism is metabolic bioactivation: CYP2E1 (and to a lesser extent CYP1A2 and CYP3A4) converts APAP to the highly reactive metabolite NAPQI, which at therapeutic doses is efficiently scavenged by hepatic glutathione (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3). At overdose levels, rapid generation of large amounts of NAPQI overwhelms glutathione reserves, causing NAPQI to react with cysteine residues on cellular proteins forming protein adducts, particularly on mitochondrial proteins (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29). Approximately half of APAP overdoses are unintentional, often resulting from opioid-acetaminophen drug combinations, while many others represent intentional acts of self-harm (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3).

Risk Factors

Environmental and Clinical Risk Factors: - Chronic alcohol abuse: Induces CYP2E1 activity, increasing NAPQI formation (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4) - Prolonged fasting and malnutrition: Depletes hepatic glutathione stores, reducing detoxification capacity (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4) - Obesity and NAFLD: NAFLD patients hospitalized for APAP overdose have a 4–7 fold higher prevalence of acute liver injury compared to those without NAFLD. Obesity-related CYP2E1 induction promotes excessive NAPQI generation and oxidative stress (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4, begriche2023acetaminopheninducedhepatotoxicityin pages 8-9) - Older age: Identified as a predisposing factor (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4) - Comedications: Antituberculosis and antiepileptic drugs can induce CYP enzymes (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4) - Diabetes (types 1 and 2): Associated with altered CYP2E1 activity and metabolic homeostasis (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4) - Low basal glutathione levels: Reduce detoxification capacity for NAPQI (begriche2023acetaminopheninducedhepatotoxicityin pages 8-9) - Concomitant hepatitis C infection: Among APAP overdose patients, those with chronic HCV had higher 3-week mortality (31% vs 17%, p = 0.01) (OpenTargets Search: toxic liver disease) - Bariatric surgery: May predispose to ALF after APAP overdose through rapid weight loss and malnutrition (begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)

Genetic Susceptibility Factors: - UGT1A polymorphisms: The UGT1A c.2042C>G polymorphism is associated with increased glucuronidation capacity and paradoxically decreased risk of unintentional APAP-induced ALF, representing a protective genetic factor (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15, begriche2023acetaminopheninducedhepatotoxicityin pages 12-14) - CYP2E1 expression/activity variation: Although CYP2E1 is the primary enzyme generating NAPQI, genetic polymorphisms contributing to inter-individual variation in CYP2E1 activity have been implicated in variable susceptibility (begriche2023acetaminopheninducedhepatotoxicityin pages 6-8)

Protective Factors

• Increased volume of distribution (in obesity): Lowers plasma APAP concentrations (begriche2023acetaminopheninducedhepatotoxicityin pages 1-3, begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• Higher hepatic glucuronidation (mediated through UGT1A9): Diverts APAP away from toxic oxidative metabolism (begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• Reduced CYP3A4 and CYP1A2 activity (observed in some obese/NAFLD patients): Decreases NAPQI generation (begriche2023acetaminopheninducedhepatotoxicityin pages 6-8, begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• n-3 polyunsaturated fatty acids: Provide hepatoprotection through anti-inflammatory and antioxidant properties (begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• Nrf2 antioxidant response pathway activation: NAPQI directly activates Nrf2, promoting adaptive antioxidant gene expression (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6)

Gene-Environment Interactions

The occurrence and severity of APAP-induced liver injury in an individual depends on a delicate balance between metabolic factors that augment NAPQI generation (CYP2E1 induction by alcohol, obesity, certain drugs) and those that mitigate hepatotoxicity (increased glucuronidation, reduced CYP3A4 activity, higher volume of distribution) (begriche2023acetaminopheninducedhepatotoxicityin pages 1-3). Conditions such as obesity and NAFLD do not uniformly increase APAP hepatotoxicity risk because some metabolic alterations favor toxicity while others limit it (begriche2023acetaminopheninducedhepatotoxicityin pages 6-8).

3. Phenotypes

Symptoms and Clinical Signs

• Early phase (0–24 hours): Nausea, vomiting, malaise, diaphoresis; patients may be asymptomatic
• HPO: HP:0002013 (Vomiting); HP:0002018 (Nausea)
• Hepatic injury phase (24–72 hours): Right upper quadrant pain, progressive elevation of transaminases (ALT, AST)
• HPO: HP:0003155 (Elevated alkaline phosphatase); HP:0002910 (Elevated hepatic transaminases)
• Peak injury/hepatic failure phase (72–96 hours): Jaundice, coagulopathy (elevated INR ≥ 1.5), hepatic encephalopathy (any degree of mental status alteration), metabolic acidosis, acute kidney injury
• HPO: HP:0000952 (Jaundice); HP:0001399 (Hepatic failure); HP:0002480 (Hepatic encephalopathy); HP:0001289 (Confusion); HP:0003256 (Coagulopathy)

Laboratory Abnormalities

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): Markedly elevated, often >1000 IU/L; notably, at therapeutic doses, up to one-third of healthy volunteers can develop ALT elevations of 3–14 fold after 3 days of treatment (NCT03602274 chunk 1)
• LOINC: 1742-6 (ALT); 1920-8 (AST)
• INR (International Normalized Ratio): Elevated ≥ 1.5, defining ALF when combined with encephalopathy (fernandez2024acuteliverfailure pages 2-3, fernandez2024acuteliverfailure pages 5-7)
• Serum acetaminophen concentration: Used for risk stratification via the Rumack-Matthew nomogram
• APAP-protein adducts (APAP-CYS): Correlate with peak aminotransferase levels and can be detected up to 12 days post-ingestion, representing specific biomarkers of toxic metabolite exposure (NCT03602274 chunk 1)
• Metabolic acidosis, elevated lactate, elevated bilirubin, elevated creatinine (in severe cases with renal involvement)

Characteristic Pathological Finding

Centrilobular (pericentral) hepatocyte necrosis is the hallmark histological finding, presenting as coagulative confluent hepatocellular necrosis in centrilobular areas (umbaugh2024biomarkerdiscoveryin pages 3-4, fernandez2024acuteliverfailure pages 5-7).

Quality of Life Impact

Severe APAP hepatotoxicity leading to ALF requires intensive care unit admission, frequently with encephalopathy and multiorgan failure, severely impacting quality of life. Survivors of ALF may experience prolonged recovery. Liver transplant recipients require lifelong immunosuppression.

4. Genetic/Molecular Information

Key Genes and Enzymes

• CYP2E1 (HGNC:2631): Primary cytochrome P450 enzyme responsible for APAP bioactivation to NAPQI. Located at chromosome 10q26.3. CYP2E1 induction by alcohol, obesity, and diabetes is a major determinant of hepatotoxicity severity (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, begriche2023acetaminopheninducedhepatotoxicityin pages 3-4, begriche2023acetaminopheninducedhepatotoxicityin pages 6-8)
• CYP1A2 (HGNC:2596): Secondary enzyme contributing to NAPQI formation
• CYP3A4 (HGNC:2637): Another CYP involved in APAP oxidation; reduced activity in some obese patients is protective (begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• UGT1A (HGNC:12530): UDP-glucuronosyltransferases responsible for APAP glucuronidation (detoxification pathway). The c.2042C>G polymorphism increases glucuronidation capacity and is protective (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15, begriche2023acetaminopheninducedhepatotoxicityin pages 12-14)
• GCLC (HGNC:4311): Glutamate-cysteine ligase catalytic subunit, the rate-limiting enzyme for glutathione synthesis. JNK-mediated degradation of GCLC impairs GSH recovery during APAP toxicity (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6)
• GSS (HGNC:4624): Glutathione synthetase involved in GSH biosynthesis
• JNK/MAPK8 (HGNC:6881): c-Jun N-terminal kinase, a central signaling kinase whose mitochondrial translocation amplifies APAP-induced hepatocyte death (jaeschke2024acetaminophenhepatotoxicityparadigm pages 6-7, jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6)

Pharmacogenomics

Genetic variation in phase I (CYP2E1, CYP1A2, CYP3A4) and phase II (UGT1A, SULT) enzymes contributes to inter-individual variability in APAP metabolism and susceptibility to hepatotoxicity (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15, begriche2023acetaminopheninducedhepatotoxicityin pages 3-4). The UGT1A c.2042C>G polymorphism is the most clearly demonstrated protective genetic variant, associated with decreased risk of unintentional APAP-induced ALF (begriche2023acetaminopheninducedhepatotoxicityin pages 12-14).

Epigenetic Information

No specific epigenetic changes (DNA methylation, histone modifications) have been definitively established as major determinants of APAP hepatotoxicity susceptibility in current literature, though gene expression regulation through Nrf2 and other transcription factors plays a role in adaptive responses (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6).

5. Environmental Information

Environmental and Lifestyle Factors

• Alcohol consumption: Chronic alcohol use induces CYP2E1, increasing NAPQI production. Alcohol-acetaminophen interactions represent a well-documented adverse drug interaction (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4)
• Fasting/malnutrition: Depletes hepatic glutathione, reducing the threshold for APAP toxicity (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4)
• Diet composition: Saturated fatty acids (e.g., from butter) increase APAP cytotoxicity more than polyunsaturated fatty acids. n-3 PUFAs may provide hepatoprotection (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6, begriche2023acetaminopheninducedhepatotoxicityin pages 9-11)
• Polypharmacy: Combination opioid-APAP products increase risk of unintentional overdose (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)

Infectious Agents

Chronic hepatitis C infection contributes to worse outcomes in APAP overdose patients (OpenTargets Search: toxic liver disease). No infectious agent directly causes APAP hepatotoxicity; however, pre-existing liver infection/inflammation may lower the threshold for toxicity.

6. Mechanism/Pathophysiology

The molecular pathogenesis of acetaminophen hepatotoxicity follows a well-characterized cascade, established primarily in mouse models with confirmed translational relevance to human pathophysiology:

Table: This table summarizes the accepted mechanistic sequence of acetaminophen hepatotoxicity from metabolic activation through mitochondrial failure, necrotic death, DAMP release, and inflammatory repair. It is useful for mapping disease biology to ontology terms and timing relationships in the standard mouse model.

Detailed Mechanistic Description

Initiation — Metabolic Bioactivation: At overdose levels, CYP2E1 in centrilobular hepatocytes metabolizes APAP to the reactive metabolite NAPQI. While therapeutic doses produce small amounts of NAPQI efficiently scavenged by hepatic GSH, overdose levels rapidly deplete GSH stores (within ~30 minutes in mice), allowing NAPQI to form covalent protein adducts, particularly on mitochondrial proteins (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3, umbaugh2024biomarkerdiscoveryin pages 3-4).

Amplification — Mitochondrial Dysfunction and JNK Signaling: Protein adducts on mitochondrial proteins trigger superoxide release from respiratory complex III, directed toward the cytosol. This cytosolic oxidant stress activates the redox-sensitive kinase ASK1, which activates downstream kinases MKK4 and JNK (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6). Activated JNK translocates to the mitochondrial outer membrane and binds the scaffold protein Sab (SH3BP5), leading to inactivation of p-Src on the inner membrane, which inhibits electron transport and increases ROS release from respiratory complex I (jaeschke2024acetaminophenhepatotoxicityparadigm pages 6-7). JNK also phosphorylates 14-3-3 proteins, releasing Bax to translocate to mitochondria, and degrades GCLC enzyme, impairing glutathione resynthesis and preventing GSH recovery (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6).

Point of No Return — DNA Fragmentation: Superoxide radicals from complex I react with nitric oxide to form peroxynitrite, which nitrates mitochondrial proteins and causes irreversible mitochondrial damage (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, jaeschke2024acetaminophenhepatotoxicityparadigm pages 6-7). Persistent peroxynitrite formation combined with loss of mitochondrial membrane potential activates the mitochondrial permeability transition (MPT), regulated by cyclophilin D (jaeschke2024acetaminophenhepatotoxicityparadigm pages 7-9). MPT opening causes mitochondrial swelling and release of intermembrane proteins—endonuclease G and apoptosis-inducing factor (AIF)—which translocate to the nucleus and cause DNA fragmentation, representing the point of no return for cell death (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, jaeschke2024acetaminophenhepatotoxicityparadigm pages 7-9).

Cell Death Mode: Despite release of cytochrome c and Smac, apoptosis is not the primary mode of cell death, potentially due to nitrotyrosine modification of these proteins impairing their pro-apoptotic function. The predominant cell death is characterized as programmed oncotic necrosis, with partial overlap of signaling events with apoptosis, ferroptosis, and pyroptosis (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3, jaeschke2024acetaminophenhepatotoxicityparadigm pages 7-9).

Sterile Inflammation and Regeneration: Necrotic hepatocytes release damage-associated molecular patterns (DAMPs) including HMGB1, mitochondrial DNA, nuclear DNA, ATP, histones, and uric acid, which bind pattern recognition receptors (TLRs, RAGE) on macrophages, triggering cytokine and chemokine expression (jaeschke2024acetaminophenhepatotoxicityparadigm pages 11-12, umbaugh2024biomarkerdiscoveryin pages 6-7). Kupffer cells generate CCL2/MCP-1 to recruit monocytes and produce IL-10 to limit pro-inflammatory responses (jaeschke2024acetaminophenhepatotoxicityparadigm pages 12-14). At moderate overdose doses, neutrophils do not worsen injury but rather promote beneficial conversion of macrophage phenotypes supporting recovery; however, at higher doses, enhanced CXCL2 levels lead to earlier, more severe neutrophil recruitment that aggravates liver injury (jaeschke2024acetaminophenhepatotoxicityparadigm pages 11-12). Monocyte-derived macrophages transition to pro-regenerative phenotypes critical for phagocytic removal of necrotic debris and hepatocyte proliferation (jaeschke2024acetaminophenhepatotoxicityparadigm pages 12-14).

Key Molecular Pathways

• MAPK/JNK signaling cascade (GO:0000165)
• Glutathione metabolic process (GO:0006749)
• Xenobiotic metabolic process (GO:0006805)
• Mitochondrial permeability transition (GO:0035794)
• Necrotic cell death (GO:0070265)
• Sterile inflammatory response (GO:0002526)
• Liver regeneration (GO:0097421)

Key Cell Types

• Pericentral/centrilobular hepatocytes (CL:0000182 — hepatocyte)
• Kupffer cells (CL:0000091 — Kupffer cell)
• Hepatic stellate cells
• Neutrophils (CL:0000775)
• Monocyte-derived macrophages (CL:0000860)
• ANXA2+ migratory hepatocytes (novel subpopulation identified in regeneration)

Advanced Technologies — Single-Cell and Spatial Transcriptomics

Recent single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics studies have provided unprecedented insights into APAP hepatotoxicity. A landmark Nature study by Matchett et al. (2024) used paired snRNA-seq and spatial profiling of healthy and ALF explant human livers to generate the first single-cell, pan-lineage atlas of human liver regeneration, discovering a novel ANXA2+ migratory hepatocyte subpopulation that mediates wound closure following APAP-induced liver injury (OpenTargets Search: toxic liver disease). scRNA-seq has also revealed that p21+ perinecrotic hepatocytes produce CXCL14 after severe APAP overdose, promoting hepatocyte injury and delaying regeneration (OpenTargets Search: toxic liver disease). Single-cell transcriptomics of human 2D and 3D liver microtissues exposed to APAP has revealed dynamic interplay between oxygen availability and drug metabolism, with hypoxic hepatocytes displaying elevated CYP450 expression while conjugation enzymes declined with increasing dose (OpenTargets Search: toxic liver disease).

7. Anatomical Structures Affected

Organ Level

• Primary organ: Liver (UBERON:0002107)
• Secondary organ involvement: Kidney (acute kidney injury in severe cases), brain (hepatic encephalopathy)
• Body systems: Digestive/hepatobiliary system, urinary system, nervous system (in ALF)

Tissue and Cell Level

• Primary tissue: Hepatic parenchyma, specifically centrilobular (zone 3) hepatocytes (UBERON:0001281 — hepatic lobule)
• Target cells: Pericentral hepatocytes (CL:0000182), expressing highest levels of CYP2E1
• Immune cells involved: Kupffer cells (CL:0000091), neutrophils (CL:0000775), monocyte-derived macrophages (CL:0000860)
• Supporting cells: Hepatic stellate cells, liver sinusoidal endothelial cells

Subcellular Level

• Mitochondria (GO:0005739): Central site of NAPQI-protein adduct formation, oxidant stress, JNK translocation, MPT, and release of endonucleases
• Endoplasmic reticulum (GO:0005783): Site of CYP450-mediated bioactivation
• Nucleus (GO:0005634): Target of endonuclease G and AIF causing DNA fragmentation
• Cytosol (GO:0005829): Site of JNK activation cascade

Localization

• Centrilobular/pericentral zone (zone 3) of the hepatic lobule (UBERON:0001281)
• Bilateral involvement
• No lateralization

8. Temporal Development

Onset

• Typical age of onset: Any age; most common in young to middle-aged adults (mean age ~30–40 years in overdose cohorts)
• Onset pattern: Acute; typically hyperacute course with rapid progression over 24–72 hours (fernandez2024acuteliverfailure pages 2-3)

Progression

APAP hepatotoxicity follows a well-defined temporal progression:

Phase I (0–24 hours): Anorexia, nausea, vomiting, malaise; patients may appear well. GSH depletion occurs within 30 minutes in mice, with APAP-protein adducts detectable in plasma by 2 hours (preceding ALT elevation) (umbaugh2024biomarkerdiscoveryin pages 3-4).

Phase II (24–72 hours): Right upper quadrant pain; progressive rise in ALT/AST; initial coagulopathy.

Phase III (72–96 hours): Peak hepatic injury with maximum transaminase elevations (often >10,000 IU/L); hepatic encephalopathy; coagulopathy; metabolic acidosis; risk of multiorgan failure. Maximum abnormalities of liver function are delayed for 3 days or more after overdose (OpenTargets Search: toxic liver disease).

Phase IV (96 hours–2 weeks): Resolution or progression to death/transplantation. ALT and necrotic area decline starting at 24 hours (in mice) and return to baseline by 72–96 hours in recoverable cases (umbaugh2024biomarkerdiscoveryin pages 3-4).

Disease Duration

Self-limited in the majority of cases with early treatment. Progression to ALF occurs in a minority of patients but can be fatal without liver transplantation.

9. Inheritance and Population

Epidemiology

• Incidence of ALF: 1–6 cases per million population per year in developed countries (fernandez2024acuteliverfailure pages 1-2)
• APAP as cause of ALF: Approximately 46% of ALF cases in the US and 60% in the UK (fernandez2024acuteliverfailure pages 2-3)
• Mortality: 28% mortality rate for APAP-related ALF (NCT03602274 chunk 1)
• Only 8% of all emergency liver transplants for ALF were related to paracetamol overdose, reflecting that most patients recover with appropriate treatment (fernandez2024acuteliverfailure pages 2-3)
• Approximately half of APAP overdoses are unintentional (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)
• Accidental overdoses typically result in more severe injury and are more frequently associated with fatal outcomes compared to intentional cases (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)

Inheritance Pattern

APAP hepatotoxicity is not a Mendelian genetic disease. It is a complex, multifactorial condition with susceptibility influenced by polygenic variation in drug-metabolizing enzymes (CYP2E1, UGT1A, SULT1A1) interacting with environmental and behavioral factors (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15, begriche2023acetaminopheninducedhepatotoxicityin pages 3-4).

Population Demographics

• Geographic distribution: Most common in developed countries where APAP is widely available; highest rates in the US, UK, Australia, and Northern Europe
• Sex ratio: Both sexes affected; some sex-dependent differences in inflammatory responses have been noted in animal models (jaeschke2024acetaminophenhepatotoxicityparadigm pages 24-25)
• The persistence of APAP overdose as a major cause of liver injury is attributed to its widespread availability and presence in numerous combination medications (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)

10. Diagnostics

Clinical Tests

• Serum acetaminophen concentration: Measured at ≥4 hours post-ingestion; used with the Rumack-Matthew nomogram to stratify risk. The nomogram allows stratification into high-risk (above 300 mg/L at 4 hours) and standard-risk (above 150 mg/L at 4 hours, or >100 mg/L in UK protocols) groups and guides NAC treatment decisions (NCT03602274 chunk 1, OpenTargets Search: toxic liver disease)
• Serum transaminases (ALT/AST): Dramatically elevated in hepatotoxicity; maximum values typically delayed 3+ days post-ingestion
• INR/Prothrombin time: Elevated INR ≥ 1.5 (with encephalopathy defines ALF)
• Arterial blood gas and lactate: Metabolic acidosis with elevated lactate
• Serum creatinine: Elevated with concomitant acute kidney injury
• Serum bilirubin: Relatively low in hyperacute paracetamol-related ALF compared to other ALF etiologies (fernandez2024acuteliverfailure pages 2-3)

Biomarkers

• APAP-protein adducts (APAP-CYS): Specific biomarkers of toxic APAP metabolite exposure; correlate with peak aminotransferase levels; detectable up to 12 days post-ingestion; point-of-care immunoassays developed (NCT03602274 chunk 1, prescott2024paracetamol(acetaminophen)poisoning pages 6-6)
• CXCL14: Novel early prognostic biomarker for poor outcome. In two independent cohorts, circulating CXCL14 concentration outperformed or equaled MELD score for discriminating nonsurvivors from survivors, with AUROC of 0.821 vs 0.787 for MELD; combining MELD and CXCL14 yielded the best AUROC of 0.860 (OpenTargets Search: toxic liver disease)
• Glutamate dehydrogenase (GDH): Mitochondrial marker of hepatocyte necrosis (umbaugh2024biomarkerdiscoveryin pages 3-4)
• HMGB1: Nuclear/extracellular DAMP marker released from necrotic hepatocytes (prescott2024paracetamol(acetaminophen)poisoning pages 6-6)
• Keratin-18 (K18): Sensitive biomarker of hepatocyte injury (prescott2024paracetamol(acetaminophen)poisoning pages 6-6)
• microRNAs: miRNA signatures for cell death and regeneration under investigation (prescott2024paracetamol(acetaminophen)poisoning pages 6-6)
• Carbamoyl phosphate synthetase 1 (CPS1): Mitochondrial enzyme released during hepatocyte necrosis (umbaugh2024biomarkerdiscoveryin pages 3-4)
• FABP1, LDH, hepcidin: Additional biomarkers being evaluated (OpenTargets Search: toxic liver disease)

Clinical Criteria

• Rumack-Matthew nomogram: Standard risk stratification tool for acute single-ingestion APAP overdose, plotting serum APAP concentration vs. time post-ingestion. Not applicable after 24 hours or for chronic/repeated supratherapeutic ingestions (NCT03602274 chunk 1)
• King's College Criteria: Prognostic criteria for determining need for liver transplantation in ALF (OpenTargets Search: toxic liver disease)
• MELD score: Used for prognostication alongside newer biomarkers

Histopathology

Coagulative confluent hepatocellular necrosis in centrilobular (zone 3) areas, with relative sparing of periportal hepatocytes (fernandez2024acuteliverfailure pages 5-7).

11. Outcome/Prognosis

Survival and Mortality

• Overall mortality rate for APAP-related ALF: approximately 28% (NCT03602274 chunk 1)
• With early NAC treatment (within 8–10 hours of ingestion), hepatotoxicity and death are largely preventable (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16)
• Patients with APAP-induced ALF are more likely to die while on the liver transplant waiting list than those with other causes of ALF (OpenTargets Search: toxic liver disease)
• Among ALF patients on transplant waitlists, 28% of deaths were due to cerebral edema complications and the remainder due to multiorgan failure (fernandez2024acuteliverfailure pages 1-2)

Prognostic Factors

• Time to treatment: Early NAC administration within 10 hours is highly effective; efficacy decreases with delayed presentation (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16, jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29)
• APAP serum concentration relative to nomogram: Patients above the 300 mg/L line at 4 hours represent high-risk cases requiring intensified treatment (OpenTargets Search: toxic liver disease)
• Intentional vs. unintentional overdose: Accidental overdoses are associated with worse outcomes (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)
• CXCL14 levels: Higher levels predict poor outcomes (AUROC 0.821) (OpenTargets Search: toxic liver disease)
• MELD score: Standard prognostic tool
• Pre-existing liver disease: Chronic HCV with APAP overdose had 31% vs 17% 3-week mortality (OpenTargets Search: toxic liver disease)
• Hepatocyte regeneration markers: Alpha-fetoprotein (AFP) and osteopontin (OPN) associated with regenerative capacity (umbaugh2024biomarkerdiscoveryin pages 3-4)

Disease Course

Most patients with appropriate early treatment recover fully. The liver has remarkable regenerative capacity, with hepatocyte proliferation and wound closure restoring liver architecture. A novel ANXA2+ migratory hepatocyte subpopulation mediates necrotic wound closure, which precedes hepatocyte proliferation during regeneration (OpenTargets Search: toxic liver disease).

12. Treatment

The following table summarizes established and emerging therapeutic options:

Table: This table summarizes established and emerging treatments for acetaminophen hepatotoxicity, including mechanisms, dosing frameworks, treatment windows, and evidence status. It is useful for comparing standard antidotal care with adjunctive and experimental strategies.

Standard of Care: N-Acetylcysteine (NAC)

NAC is the only clinically approved antidote and remains the standard of care (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16). Its mechanism involves providing cysteine for hepatic glutathione resynthesis to scavenge NAPQI and peroxynitrite inside mitochondria, supporting mitochondrial bioenergetics rather than directly reacting with NAPQI (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16, jaeschke2024acetaminophenhepatotoxicityparadigm pages 16-17). Early administration within 8–10 hours of overdose is highly effective (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16). Multiple IV protocols exist including the traditional three-bag regimen (150 mg/kg over 15 min to 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours; total 300 mg/kg over ~21 hours) and the SNAP trial protocol (300 mg/kg over 12 hours) (rumack2025acetylcysteinetreatmentof pages 13-15, rumack2025acetylcysteinetreatmentof pages 10-13). The oral protocol consists of 140 mg/kg loading dose followed by 70 mg/kg every 4 hours for 17 additional doses over 72 hours (total 1330 mg/kg) (rumack2025acetylcysteinetreatmentof pages 10-13, rumack2025acetylcysteinetreatmentof pages 7-9). NAC treatment stopping criteria include acetaminophen concentration <10 µg/mL, INR <2.0, normalized or decreasing transaminases, and clinical improvement (rumack2025acetylcysteinetreatmentof pages 13-15). MAXO terms: MAXO:0010033 (drug therapy).

Fomepizole (4-Methylpyrazole)

Fomepizole offers a mechanistically distinct benefit from NAC by inhibiting CYP2E1-mediated NAPQI formation and preventing JNK activation, making it particularly useful for massive ingestions, delayed presentations, or patients with renal injury where NAC is ineffective (rumack2025acetylcysteinetreatmentof pages 15-17, rumack2025acetylcysteinetreatmentof pages 13-15, jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, prescott2024paracetamol(acetaminophen)poisoning pages 6-7). A Phase 2 clinical trial (NCT05517668) was initiated to evaluate fomepizole efficacy in acetaminophen overdose, though it was terminated. MAXO terms: MAXO:0010033 (drug therapy).

Liver Transplantation

Emergency liver transplantation remains the only curative option for patients with fulminant hepatic failure who do not respond to medical therapy. Candidacy is typically determined by prognostic criteria such as the King's College Criteria (prescott2024paracetamol(acetaminophen)poisoning pages 6-7, fernandez2024acuteliverfailure pages 2-3). MAXO terms: MAXO:0001175 (organ transplantation).

Experimental Therapies

• Calmangafodipir: A superoxide dismutase mimetic targeting mitochondrial oxidant stress, tested alongside NAC in the POP clinical trial (rumack2025acetylcysteinetreatmentof pages 15-17, bateman2023largeparacetamoloverdose—higher pages 5-5, prescott2024paracetamol(acetaminophen)poisoning pages 6-7)
• PEG-TPO (thrombopoietin mimetic peptide): Promotes liver recovery at 24 hours when NAC is less effective (rumack2025acetylcysteinetreatmentof pages 15-17)
• Adenosine A2B receptor activators: Decrease necrosis and enhance reparative macrophage infiltration (rumack2025acetylcysteinetreatmentof pages 15-17)
• Wharton's Jelly mesenchymal stem cells: Protect mitochondrial function (rumack2025acetylcysteinetreatmentof pages 15-17)
• Lipid-nanoparticle-encapsulated mRNA of growth factors (HGF/EGF): For enhancing hepatic regeneration in late presentation (rumack2025acetylcysteinetreatmentof pages 15-17, jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29)

13. Prevention

Primary Prevention

• Dose limitation: FDA mandate limiting acetaminophen in prescription combination opioid products to 325 mg per dosage unit (OpenTargets Search: toxic liver disease)
• Package size restrictions: UK legislation limiting pack sizes of paracetamol sold over the counter
• Public education: Awareness campaigns about APAP content in combination medications to prevent unintentional overdose (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3)
• Labeling requirements: Clear labeling of APAP-containing products
• MAXO terms: MAXO:0000058 (health education)

Secondary Prevention

• Early recognition and NAC administration: The Rumack-Matthew nomogram enables risk stratification within 4 hours of presentation, guiding timely antidote administration (NCT03602274 chunk 1)
• Novel biomarkers for early detection: APAP-protein adducts, CXCL14, and K18 offer promise for earlier identification of patients at risk of liver injury (NCT03602274 chunk 1, prescott2024paracetamol(acetaminophen)poisoning pages 6-6, OpenTargets Search: toxic liver disease)
• Activated charcoal: GI decontamination within 1–2 hours of ingestion reduces absorption

Tertiary Prevention

• Extended NAC treatment: For patients with persistent toxicity markers
• Intensified NAC dosing: Higher doses for patients above the 300 mg/L nomogram treatment line (OpenTargets Search: toxic liver disease)
• Monitoring for complications: Serial assessment of hepatic function, coagulation, renal function, and neurological status

14. Other Species / Natural Disease

Veterinary Relevance

Acetaminophen hepatotoxicity occurs naturally in several animal species, with particular veterinary importance: - Cats (NCBI Taxon:9685): Extremely sensitive due to deficiency in UGT1A6 (glucuronidation), leading to accumulation of NAPQI; methemoglobinemia is a prominent feature - Dogs (NCBI Taxon:9615): Susceptible to hepatotoxicity at supratherapeutic doses - Pigs (NCBI Taxon:9823): Used as large animal models

Comparative Biology

The metabolic pathways (CYP2E1-mediated bioactivation, glutathione conjugation, glucuronidation, sulfation) are highly conserved across mammalian species, though relative contributions of individual pathways vary, explaining species-specific susceptibility patterns. Rats are notably less sensitive than mice to APAP hepatotoxicity due to differences in CYP enzyme expression and metabolic capacity.

15. Model Organisms

Mouse Models

The mouse is the primary model organism for studying APAP hepatotoxicity, with demonstrated translational relevance to human pathophysiology (jaeschke2024acetaminophenhepatotoxicityparadigm pages 17-19).

Dose Models: - 300 mg/kg APAP (C57Bl/6 mice): Represents a moderate overdose producing a uniform sequence of pathophysiological events including GSH depletion, JNK phosphorylation, centrilobular necrosis, sterile inflammation, and recovery. Models patients who recover with supportive care (umbaugh2024biomarkerdiscoveryin pages 12-14, umbaugh2024biomarkerdiscoveryin pages 4-6, umbaugh2024biomarkerdiscoveryin pages 3-4) - 600 mg/kg APAP: Represents a severe overdose with prolonged injury, decreased hepatocyte proliferation, increased cell cycle arrest, and reduced survival. May better represent patients progressing to ALF (umbaugh2024biomarkerdiscoveryin pages 4-6, umbaugh2024biomarkerdiscoveryin pages 3-4)

Mouse Strains Used: - C57Bl/6, C57Bl/6J, C57Bl/6N (standard strains) (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6) - FVB/N mice (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6) - Genetically obese models: db/db, ob/ob mice (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6, begriche2023acetaminopheninducedhepatotoxicityin pages 14-15) - KK-A(y) diabetic mice (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15)

Phenotype Recapitulation: - Conserved injury mechanisms: APAP bioactivation to NAPQI, mitochondrial toxicity, centrilobular necrosis, and necrosis as the primary cell death mode are all recapitulated (umbaugh2024biomarkerdiscoveryin pages 12-14) - Biomarkers identified in mice (GDH, mtDNA, nuclear DNA, CPS1, APAP-protein adducts) correlate with human pathology (umbaugh2024biomarkerdiscoveryin pages 12-14)

Limitations: - Significant temporal differences: key events occur much faster in mice than in humans. For example, NAC loses efficacy by 3–6 hours in mice but remains effective up to 8–10 hours in human patients (umbaugh2024biomarkerdiscoveryin pages 4-6) - Higher APAP doses used relative to human toxic doses - Some immune responses may differ between species (jaeschke2024acetaminophenhepatotoxicityparadigm pages 24-25)

Other Models

• Rat models: Zucker fa/fa rats, diet-induced NAFLD models; rats are generally less sensitive to APAP hepatotoxicity than mice (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6)
• In vitro systems: Primary human hepatocytes, HepaRG cells, L02 cells, hepatocyte-like organoids (HL-ICOs), and 3D spheroid models composed of primary human hepatocytes, Kupffer cells, and liver endothelial cells (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6, OpenTargets Search: toxic liver disease)
• Resources: MGI (Mouse Genome Informatics), IMPC (International Mouse Phenotyping Consortium)

Summary

Acetaminophen hepatotoxicity remains a major global public health challenge as the leading cause of drug-induced acute liver failure in developed countries. The pathophysiology is among the most thoroughly understood of any drug toxicity, with a well-defined cascade from CYP2E1-mediated NAPQI formation through mitochondrial dysfunction, JNK-mediated amplification, and programmed necrotic cell death (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29, jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3). N-acetylcysteine remains the standard antidote when administered early, with fomepizole emerging as a promising adjunct for high-risk cases (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16, jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29). Recent advances in single-cell transcriptomics and spatial profiling have uncovered novel aspects of liver regeneration including ANXA2+ migratory hepatocytes and have identified new prognostic biomarkers such as CXCL14 (OpenTargets Search: toxic liver disease). Multiple experimental therapies targeting mitochondrial protection and liver regeneration are under investigation (rumack2025acetylcysteinetreatmentof pages 15-17). The translational relevance of mouse models has been a cornerstone of mechanistic discovery, though important temporal and quantitative differences exist between species (umbaugh2024biomarkerdiscoveryin pages 4-6, jaeschke2024acetaminophenhepatotoxicityparadigm pages 17-19). Prevention strategies including dose limitations, package size restrictions, public education, and early clinical risk stratification via the Rumack-Matthew nomogram remain critical to reducing the burden of this preventable form of liver injury.

References

1. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 1-3): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

2. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 27-29): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

3. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 16-17): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

4. (umbaugh2024biomarkerdiscoveryin pages 3-4): David S Umbaugh and Hartmut Jaeschke. Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight. Expert Review of Clinical Pharmacology, 17:143-155, Jan 2024. URL: https://doi.org/10.1080/17512433.2024.2306219, doi:10.1080/17512433.2024.2306219. This article has 5 citations and is from a peer-reviewed journal.

5. (fernandez2024acuteliverfailure pages 5-7): Javier Fernández, Octavi Bassegoda, David Toapanta, and William Bernal. Acute liver failure: a practical update. JHEP Reports, 6:101131, Sep 2024. URL: https://doi.org/10.1016/j.jhepr.2024.101131, doi:10.1016/j.jhepr.2024.101131. This article has 80 citations and is from a peer-reviewed journal.

6. (fernandez2024acuteliverfailure pages 2-3): Javier Fernández, Octavi Bassegoda, David Toapanta, and William Bernal. Acute liver failure: a practical update. JHEP Reports, 6:101131, Sep 2024. URL: https://doi.org/10.1016/j.jhepr.2024.101131, doi:10.1016/j.jhepr.2024.101131. This article has 80 citations and is from a peer-reviewed journal.

7. (fernandez2024acuteliverfailure pages 1-2): Javier Fernández, Octavi Bassegoda, David Toapanta, and William Bernal. Acute liver failure: a practical update. JHEP Reports, 6:101131, Sep 2024. URL: https://doi.org/10.1016/j.jhepr.2024.101131, doi:10.1016/j.jhepr.2024.101131. This article has 80 citations and is from a peer-reviewed journal.

8. (begriche2023acetaminopheninducedhepatotoxicityin pages 3-4): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

9. (begriche2023acetaminopheninducedhepatotoxicityin pages 8-9): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

10. (OpenTargets Search: toxic liver disease): Open Targets Query (toxic liver disease, 28 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

11. (begriche2023acetaminopheninducedhepatotoxicityin pages 9-11): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

12. (begriche2023acetaminopheninducedhepatotoxicityin pages 14-15): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

13. (begriche2023acetaminopheninducedhepatotoxicityin pages 12-14): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

14. (begriche2023acetaminopheninducedhepatotoxicityin pages 6-8): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

15. (begriche2023acetaminopheninducedhepatotoxicityin pages 1-3): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

16. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 4-6): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

17. (NCT03602274 chunk 1): Caroline Samer. APAP Hepatotoxicity After Therapeutic Doses. University Hospital, Geneva. 2015. ClinicalTrials.gov Identifier: NCT03602274

18. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 6-7): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

19. (begriche2023acetaminopheninducedhepatotoxicityin pages 5-6): Karima Begriche, Clémence Penhoat, Pénélope Bernabeu-Gentey, Julie Massart, and Bernard Fromenty. Acetaminophen-induced hepatotoxicity in obesity and nonalcoholic fatty liver disease: a critical review. Livers, 3:33-53, Jan 2023. URL: https://doi.org/10.3390/livers3010003, doi:10.3390/livers3010003. This article has 36 citations.

20. (umbaugh2024biomarkerdiscoveryin pages 14-15): David S Umbaugh and Hartmut Jaeschke. Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight. Expert Review of Clinical Pharmacology, 17:143-155, Jan 2024. URL: https://doi.org/10.1080/17512433.2024.2306219, doi:10.1080/17512433.2024.2306219. This article has 5 citations and is from a peer-reviewed journal.

21. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 7-9): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

22. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 11-12): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

23. (umbaugh2024biomarkerdiscoveryin pages 6-7): David S Umbaugh and Hartmut Jaeschke. Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight. Expert Review of Clinical Pharmacology, 17:143-155, Jan 2024. URL: https://doi.org/10.1080/17512433.2024.2306219, doi:10.1080/17512433.2024.2306219. This article has 5 citations and is from a peer-reviewed journal.

24. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 12-14): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

25. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 24-25): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

26. (prescott2024paracetamol(acetaminophen)poisoning pages 6-6): Laurie F. Prescott. Paracetamol (acetaminophen) poisoning: the early years. British Journal of Clinical Pharmacology, 90:127-134, Sep 2024. URL: https://doi.org/10.1111/bcp.15903, doi:10.1111/bcp.15903. This article has 43 citations and is from a domain leading peer-reviewed journal.

27. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 14-16): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

28. (rumack2025acetylcysteinetreatmentof pages 13-15): Barry H. Rumack. Acetylcysteine treatment of acetaminophen overdose: foundational and clinical development. Livers, 5:20, Apr 2025. URL: https://doi.org/10.3390/livers5020020, doi:10.3390/livers5020020. This article has 2 citations.

29. (rumack2025acetylcysteinetreatmentof pages 10-13): Barry H. Rumack. Acetylcysteine treatment of acetaminophen overdose: foundational and clinical development. Livers, 5:20, Apr 2025. URL: https://doi.org/10.3390/livers5020020, doi:10.3390/livers5020020. This article has 2 citations.

30. (rumack2025acetylcysteinetreatmentof pages 7-9): Barry H. Rumack. Acetylcysteine treatment of acetaminophen overdose: foundational and clinical development. Livers, 5:20, Apr 2025. URL: https://doi.org/10.3390/livers5020020, doi:10.3390/livers5020020. This article has 2 citations.

31. (bateman2023largeparacetamoloverdose—higher pages 5-5): D. Nicholas Bateman. Large paracetamol overdose—higher dose acetylcysteine is required. British Journal of Clinical Pharmacology, 89:34-38, Feb 2023. URL: https://doi.org/10.1111/bcp.15201, doi:10.1111/bcp.15201. This article has 11 citations and is from a domain leading peer-reviewed journal.

32. (rumack2025acetylcysteinetreatmentof pages 15-17): Barry H. Rumack. Acetylcysteine treatment of acetaminophen overdose: foundational and clinical development. Livers, 5:20, Apr 2025. URL: https://doi.org/10.3390/livers5020020, doi:10.3390/livers5020020. This article has 2 citations.

33. (prescott2024paracetamol(acetaminophen)poisoning pages 6-7): Laurie F. Prescott. Paracetamol (acetaminophen) poisoning: the early years. British Journal of Clinical Pharmacology, 90:127-134, Sep 2024. URL: https://doi.org/10.1111/bcp.15903, doi:10.1111/bcp.15903. This article has 43 citations and is from a domain leading peer-reviewed journal.

34. (jaeschke2024acetaminophenhepatotoxicityparadigm pages 17-19): Hartmut Jaeschke and Anup Ramachandran. Acetaminophen hepatotoxicity: paradigm for understanding mechanisms of drug-induced liver injury. Annual review of pathology, 19:453-478, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-094016, doi:10.1146/annurev-pathmechdis-051122-094016. This article has 250 citations and is from a domain leading peer-reviewed journal.

35. (umbaugh2024biomarkerdiscoveryin pages 12-14): David S Umbaugh and Hartmut Jaeschke. Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight. Expert Review of Clinical Pharmacology, 17:143-155, Jan 2024. URL: https://doi.org/10.1080/17512433.2024.2306219, doi:10.1080/17512433.2024.2306219. This article has 5 citations and is from a peer-reviewed journal.

36. (umbaugh2024biomarkerdiscoveryin pages 4-6): David S Umbaugh and Hartmut Jaeschke. Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight. Expert Review of Clinical Pharmacology, 17:143-155, Jan 2024. URL: https://doi.org/10.1080/17512433.2024.2306219, doi:10.1080/17512433.2024.2306219. This article has 5 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02